Osteologix, Inc. (OTC BB: OLGX), a specialty biopharmaceutical company, has dedicated their efforts to improving the health of those afflicted with musculoskeletal diseases through the development of innovative therapies. NB S101, the company’s lead investigational product candidate, is an innovative pharmaceutical agent designed to treat and prevent osteoporosis. Their mission is to partner with the healthcare community to apply new scientific information to the development of beneficial products. For more information please visit www.osteologix.com.
- 18 years ago
QualityStocks
Osteologix, Inc. (OTC BB: OLGX)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Hallmark Venture Group, Inc. (OTC: HLLK) Completes Drone Technology Acquisition, Transitions to Operating Business
Hallmark Venture Group (OTC: HLLK) announced the completion of a strategic transaction that transforms the company from…
-
QualityStocksNewsBreaks – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) Featured in BioMedWire Editorial on DNA Repair Cancer Therapies
This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising. Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) announced…
-
QualityStocksNewsBreaks – Safe Pro Group Inc. (NASDAQ: SPAI) Releases RoadSight UGV Demonstration Video
Safe Pro Group (NASDAQ: SPAI), has released a demonstration video highlighting its new RoadSight capability,…